Correlation of MLH1 and MGMT expression and promoter methylation with genomic instability in patients with thyroid carcinoma

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Santos, Juliana Carvalho ^a   Bastos, André Uchimura ^b   Cerutti, Janete Maria ^b   Ribeiro, Marcelo Lima ^a  

^a UNIVERSIDADE SÃO FRANCISCO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

DNA methylation; DNA repair; Microsatellite instability; Thyroid carcinoma

Indexed keywords

B RAF KINASE; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICROSATELLITE DNA; PROTEIN MLH1;

ARTICLE; BRAF GENE; CANCER PATIENT; CORRELATION ANALYSIS; DNA METHYLATION; GENE ACTIVITY; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC REGULATION; HUMAN; HUMAN TISSUE; IDH1 GENE; MAJOR CLINICAL STUDY; MGMT GENE; MICROSATELLITE INSTABILITY; MLH1 GENE; NRAS GENE; ONCOGENE; PAPILLARY CARCINOMA; PHENOTYPE; THYROID CARCINOMA; THYROID SURGERY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARCINOMA; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; HUMANS; MICROSATELLITE INSTABILITY; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84873701225     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-79     Document Type: Article

References (29)

1. SEER Cancer Statistics Review, 1975-2006 Bethesda, MD: National Cancer Institute, Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK.
2. Mingzhao X. Recent advances in molecular biology of thyroid cancer and their clinical implications. Otolaryngol Clin North Am 2008, 41:1135-1146. 10.1016/j.otc.2008.07.001, 2615411, 19040974.
3. Kohno M, Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy. Ann Med 2006, 38:200-211. 10.1080/07853890600551037, 16720434.
4. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006, 6:292-306. 10.1038/nrc1836, 16557281.
5. Ciampi R, Nikiforov YE. Minireview: RET/PTC Rearrangements and BRAF Mutations in Thyroid Tumorigenesis. Endocrinology 2007, 148:936-941. 937.
6. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954. 10.1038/nature00766, 12068308.
7. Oler G, Ebina KN, Jr Michaluart P, Kimura ET, Cerutti J. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clin Endocrinol (Oxf) 2005, 624:509-511.
8. Oler G, Cerutti JM. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer 2009, 115:972-980. 10.1002/cncr.24118, 19152441.
9. Minoletti F, Butti MG, Coronelli S, Miozzo M, Sozzi G, Pilotti S, Tunnacliffe A, Pierotti MA, Bongarzone I. The two genes generating RET/PTC3 are localised in chromosomal band 10q11.2. Genes Chromosomes Cancer 1994, 11:51-57. 10.1002/gcc.2870110108, 7529046.
10. Guerra A, Sapio MR, Marotta V, Campanile E, Moretti MI, Deandrea M, Motta M, Limone PP, Fenzi G, Rossi G, Vitale M. Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application. Endocr J 2011, 58:31-38. 10.1507/endocrj.K10E-260, 21173509.
11. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P, Basolo F. Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma. J Clin Endocrinol Metab 2007, 92:4085-4090. 10.1210/jc.2007-1179, 17785355.
12. Hemerly JP, Bastos AU, Cerutti JM. Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas. Eur J Endocrinol 2010, 163:747-755. 10.1530/EJE-10-0473, 20702649.
13. Murugan AK, Bojdani E, Xing M. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys Res Commun 2010, 393:555-559. 10.1016/j.bbrc.2010.02.095, 2838977, 20171178.
14. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A, Rodolfo M, Scarpa A, Felicioni L, Buttitta F, Malatesta S, Marchetti A, Bardelli A. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 2009, 30:7-11. 10.1002/humu.20937, 19117336.
15. de Vogel S, Weijenberg MP, Herman JG, Wouters KA, de Goeij AF, van den Brandt PA, de Bruïne AP, van Engeland M. MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events. Ann Oncol 2009, 20:1216-1222. 10.1093/annonc/mdn782, 19164452.
16. Arnaldi LA, Borra RC, Maciel RM, Cerutti JM. Gene expression profiles reveal that DCN, DIO1, and DIO2 are underexpressed in benign and malignant thyroid tumors. Thyroid 2005, 153:210-221.
17. Cerutti JM, Delcelo R, Amadei MJ, Nakabashi C, Maciel RM, Peterson B, Shoemaker J, Riggins GJ. A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin Invest 2004, 113:1234-1242. 385398, 15085203.
18. Kang GH, Shim YH, Jung HY, Kim WH, Ro JY, Rhyu MG. CpG island methylation in pre- malignant stages of gastric carcinoma. Cancer Res 2001, 61:2847-2851.
19. Guan H, et al. Hypermethylation of the DNA mismatch repair Gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer. Am Cancer Soc 2008, 113:247-255.
20. Shima K, Morikawa T, Baba Y, Nosho K, Suzuki M, Yamauchi M, Hayashi M, Giovannucci E, Fuchs CS, Ogino S. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes Control 2011, 22:301-309. 10.1007/s10552-010-9698-z, 3278857, 21140203.
21. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998, 95:6870-6875. 10.1073/pnas.95.12.6870, 22665, 9618505.
22. Jass JR. Towards a molecular classification of colorectal cancer. Int J Colorectal Dis 1999, 14:194-200. 10.1007/s003840050211, 10647627.
23. Onda M, Nakamura I, Suzuki S, Takenoshita S, Brogren C-H, Stampanoni S, Li D, Rampino N. Microsatellite instability in thyroid cancer: hot spots, clinicopathological implications, and prognostic significance. Clin Cancer Res 2001, 7:3444-3449.
24. Mitmaker E, Alvarado C, Bégin LR, Trifiro M. Microsatellite instability in benign and malignant thyroid neoplasms. J Surg Res 2008, 150:40-48. 10.1016/j.jss.2007.12.760, 18243241.
25. Soares P, dos Santos NR, Seruca R, Lothe RA, Sobrinho-Simões M. Benign and malignant thyroid lesions show instability at microsatellite loci. Eur J Cancer 1997, 33:293-296. 10.1016/S0959-8049(96)00457-1, 9135503.
26. Lazzereschi D, Palmirotta R, Ranieri A, Ottini L, Verì MC, Cama A, Cetta F, Nardi F, Colletta G, Mariani-Costantini R. Microsatellite instability in thyroid tumours and tumourlike lesions. Br J Cancer 1999, 79:340-345. 10.1038/sj.bjc.6690054, 2362211, 9888478.
27. Imai K, Yamamoto H. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 2008, 29:673-680.
28. Vaish M, Mishra A, Kaushal M, Mishra SK, Mittal B. Microsatellite instability and its correlation with clinicopathological features in a series of thyroid tumors prevalent in iodine deficient areas. Exp Mol Med 2004, 36(2):122-129. 10.1038/emm.2004.18, 15150440.
29. Whitehall VL, Walsh MD, Young J, Leggett BA, Jass JR. Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. Cancer Res 2001, 61:827-830.